


















































































































































































































































































































Schutz & Abbott Success Complications 
1 Diagnostic ERCP 92-96 % 1.5-3 % 
2 Therapeutic ERCP 
EST, small CBDS, nasobiliary 
drainage 
100 % 10 % 
3 Complex diagnostic  
B2, brush cytology 
80-100 % 17-20 % 
4 Complex therapeutic 
Large CBDS, dilatation, stents 
95-97 % 3 % 




cholangioscopy, all pancreatic 
interventions 
































































	 OR	(95	%CI)	 Relative	risk	SOD	 1.9 (1.4 – 2.6)	 8.6 % vs. 2.5 %	Female	 3.5 (1.1 – 10.6)	 4.0 % vs. 2.1 %	Previous	pancreatitis	 2.5 (1.9 – 3.1)	 6.7 % vs. 3.8 %	Younger	age	 1.1 – 2.9	 6.2 % vs. 2.6 %	Previous	PEP	 8.7 (3.2 – 23.9)	 30 % vs. 3.5 %	No	chronic	pancreatitis	 1.9 (1.0 – 3.5)	 4.0 % vs. 3.1 %	Normal	bilirubin	level	 1.9 (1.2 – 2.9)	 4.2 % vs. 1.4 %	Non-dilated	bile	duct	 - 3.8 % vs. 2.3 %		




















































(ESGE)	Guideline.	Endoscopy,	2014;	46(9):	799-815.				 Author	 Year	 n	 PEP	NSAID		
PEP	placebo	 OR	(95	%	CI)	 NNT	










































































































































procedures	into	three	different	classes	in	relation	to	their	complexity		Initially,	 the	HOUSE	classification	was	developed	and	 launched	 into	clinical	practice	 to	gain	financial	reimbursement	and	control	of	the	increasing	costs	for	endoscopic	devices	used	 as	 well	 as	 the	 prolonged	 procedure	 times	 required	 to	 complete	 the	 expanding	complexity	of	ERCP	examinations	done	at	the	Karolinska	University	Hospital,	Huddinge,	Stockholm,	Sweden,	which	over	time	has	evolved	into	a	national	tertiary-referral	center	for	advanced	endoscopy	in	Sweden.	Concomitantly,	there	was	a	continuous	demand	for	
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4.1.5	Comments	The	main	finding	of	this	paper	was	that	we	found	a	significant	reduction	of	2.6	%	(14.2	%	 vs	 11.6	%)	 in	 overall	 adverse	 effects	 if	 prophylactic	 antibiotics	were	 administered	adjacent	 to	 the	 ERCP	 procedure.	 However,	 this	 figure	 must	 be	 put	 in	 relation	 to	 the	negative	side	effects	of	antibiotics	(e.g.,	the	development	of	antibiotic	resistance	or	side	effects	 for	 the	 patients).	 Although	 an	 OR	 reduction	 for	 adverse	 events	 of	 26	 %	 was	demonstrated,	 if	 antibiotic	 prophylaxis	 was	 given	 in	 conjunction	 with	 the	 ERCP,	 the	number	of	patients	 still	needed	 treat	 to	avoid	one	 complication	was	38,	which	 cannot	justify	a	policy	of	giving	every	routine	ERCP	antibiotics	prophylactically.	These	findings	are	 in	 line	with	a	previous	meta-analysis	by	Bai	 from	2009	(Bai,	Y.,	et	al.,	2009),	which	does	not	recommend	prophylactic	antibiotics	in	general.		Another	 finding	 of	 our	 study	 is	 that	 patients	 with	 jaundice	 seem	 to	 have	 a	 special	beneficial	 effect	 from	 prophylactic	 antibiotics	 with	 an	 OR	 reduction	 of	 32	 %	 when	
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antibiotics	are	given	in	this	group	with	a	24	%	OR	reduction	on	the	septic	complications.	This	corresponds	well	to	the	meta-analysis	by	Brand	from	2010	(Brand,	M.,	et	al.,	2010),	which	 states	 that	prophylactic	 antibiotics	 seem	 to	 reduce	cholangitis,	 especially	 in	 the	patients	where	 drainage	 of	 the	 bile	 duct	 cannot	 be	 completely	 achieved	 and	 suggests	that	prophylactic	 antibiotics	 could	be	 reserved	 for	 these	patients.	The	problem	 is	 that	this	situation	of	undrained	bile	ducts	cannot	be	anticipated	prior	to	the	ERCP	when	the	antibiotics	should	be	administrated,	and	perhaps	prophylactic	antibiotics	could	be	given	to	these	patients	with	a	higher	risk	of	unsuccessful	complete	drainage,	such	as	patients	with	hilar	strictures	or	primary	sclerosing	cholangitis.		A	 major	 problem	 of	 the	 findings	 of	 the	 previous	 meta-analyses	 on	 the	 subject	 of	prophylactic	 antibiotics	 in	 ERCP	 is	 that	 the	 number	 of	 randomized	 studies	 is	 limited		
(Brandes,	J.	W.,	et	al.	1981,	Byl,	B.,	et	al.,	1995,	Llach,	J.,	et	al.,	2006,	Lorenz,	R.,	et	al.,	1996,	
Niederau,	C.,	et	al.,	1994,	Raty,	S.,	et	al.,	2001,	Sauter,	G.,	et	al.,	1990,	Spicak,	J.,	et	al.,	2001,	
van	den	Hazel,	S.	 J.,	et	al.,	1996).	Most	of	 the	 studies	were	 small,	 the	 results	 conflicting	and	most	of	 the	studies	were	 from	the	1990s	with	 the	 latest	study	conducted	 in	2006	
(Llach,	 J.,	 et	 al.,	 2006).	 Therefore,	 in	 conclusion,	more	 randomized	 studies	 are	 needed	that	include	modern	antibiotics	and	modern	endoscopic	settings	to	resolve	the	issue	of	when	prophylactic	antibiotics	should	be	administered	in	ERCP.	One	strength	of	our	study	is	the	low	risk	of	selection	bias,	since	it	is	based	on	data	from	a	national	 registry,	 representing	 all	 types	 of	 endoscopic	 centers	 performing	 ERCP	with	different	volumes	of	patients	and	endoscopists	with	different	experiences.	Additionally,	the	 procedures	were	 undertaken	 on	 a	 great	 variety	 of	 patients	with	 various	 different	indications	 for	 the	 ERCP	 procedure	 –	 from	 common,	 less	 complicated	 ones	 to	 rare,	complex	ERCPs.	The	risk	of	random	error	 is	also	small	 in	a	study	of	 this	size,	as	 is	 the	
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risk	 of	 systematic	 errors	 since	 the	 register	 includes	 90	%	 of	 all	 ERCPs	 performed	 in	Sweden.	Another	strength	of	the	study	is	the	GallRiks	Registry´s	good	validity	with	a	match	with	the	patient	records	of	more	than	97	%	(Enochsson,	L.,	et	al.,	2013,	Rystedt,	J.,	et	al.,	2014),	minimizing	the	risk	for	misclassification.	There	also	seems	to	be	a	good	correlation	regarding	 the	basic	characteristics	between	the	 groups	 receiving	 prophylactic	 antibiotics	 compared	 to	 the	 groups	 that	 were	 not	given	prophylactic	antibiotics,	regarding	gender,	ASA	and	age,	although	the	age	differed	slightly	 between	 the	 groups	 (65.9	 vs	 67.4	 years,	 p<0.0001).	 Parameters	 are	 often	significantly	 different	 in	 large,	 national,	 register-based	 studies	 like	 this	 (mass	significance),	 but	 when	 looking	 at	 its	 clinical	 significance,	 the	 difference	 between	 66	years	and	67.5	years	probably	has	a	very	modest	effect	on	the	outcome	studied.	We	also	identified	other	risk	factors	for	ERCP	related	adverse	events	in	our	study.	Many	of	them	were	known	from	previous	studies	(Freeman,	M.	L.,	et	al.,	2001,	Freeman,	M.	L.,	et	
al.,	1996)	(e.g.,	the	time	of	the	ERCP	procedure	[>30	minutes],	which	increases	the	risk	for	complications).	Of	course,	it	is	not	the	time	itself	that	affects	the	complication	rates	but	the	things	being	performed	during	the	longer	procedure.	It	is	probable	that	these	30	minutes	 contain	 multiple	 cannulation	 attempts,	 guidewire	 passages	 to	 the	 pancreatic	duct	and	an	over-representation	of	more	precut	sphincterotomies	in	this	group,	where	time	represents	a	surrogate	marker	for	other	events	that	represent	the	real	risk	factors	for	postoperative	complications.	Lower	 age	 (<70	 years)	 is	 another	 factor	 that	 was	 found	 to	 increase	 the	 risk	 of	complications	 in	our	study,	which	 is	an	opposite	phenomena	compared	to	many	other	surgical	 interventions.	We	 interpret	 this	 by	 stating	 that	 younger	 people	 have	 a	more	
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viable	pancreas,	thereby	they	are	more	reactive	when	being	subject	to	an	ERCP	and	have	a	higher	risk	for	developing	a	PEP.	Another	 well-known	 risk	 factor	 in	 ERCP,	 which	 we	 also	 confirmed	 in	 this	 study,	 is	cannulation	 of	 the	 pancreatic	 duct	 (Freeman,	 M.	 L.,	 et	 al.,	 2001).	 We	 also	 noticed	 a	slightly	elevated	complication	risk	 in	patients	with	 jaundice	prior	 to	 the	ERCP,	but	we	did	 not	manage	 to	 demonstrate	 any	differences	 in	 adverse	 events	whether	 or	 not	 the	bile	 duct	was	 cannulated.	We	 also	 could	 not	 identify	 any	 differences	 in	 complications	depending	 on	 case	 volume	 of	 the	 center	 performing	 the	 ERCPs,	 which	 speculatively	could	be	explained	because	 larger	centers	have	more	endoscopists,	which	reduces	 the	number	of	investigations	per	endoscopist;	also,	larger	centers	have	more	trainees,	which	may	 increase	 the	 risk	 of	 complications,	 and	 larger	 centers	 also	 handle	more	 complex	cases,	which	may	result	in	more	adverse	events.	There	 are	 also	 weaknesses	 of	 register-based	 studies.	 Since	 they	 are	 not	 randomized,	there	 is	 always	 a	 risk	 for	 confounding	 factors,	 and	 there	 might	 be	 factors	 that	 are	unknown	and	thereby	cannot	have	been	compensated	for	in	the	multivariate	regression	analysis.	There	 is	also	a	risk	of	case-mixing	within	the	study	population—for	example,	the	 endoscopist	may	 be	more	 prone	 to	 give	 antibiotics	 if	 he	 suspects	 the	 ERCP	 to	 be	more	complicated.	A	final	consideration	is	the	long	inclusion	period	of	the	study	(2005-2013).	 This	 time	 period	 encompasses	 technical	 development	 and	 the	 introduction	 of	new	antibiotics,	and	these	factors	must	also	be	taken	into	account	when	interpreting	the	results	of	the	study.	In	conclusion,	our	study	shows	that	prophylactic	antibiotics	reduce	the	risk	of	adverse	events	by	2.6	%,	but	this	is	not	sufficient	to	make	a	general	recommendation	
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4.2.5	Comments	One	 important	 finding	 in	 this	study	was	 that	we	demonstrated	a	more	 than	 three-fold	increase	 in	 the	 OR	 (OR	 3.07)	 for	 developing	 PEP	 if	 the	 pancreatic	 duct	 had	 been	cannulated	during	the	ERCP	procedure	(7.9	%	vs	2.6	%,	p<0.0001),	which	is	in	line	with	previous	 studies	 (Cotton,	P.	B.,	 et	 al.,	 2009,	Cotton,	P.	B.,	 et	 al.,	 1991).	 The	 other	major	finding	of	the	study	was	a	decreased	risk	of	developing	PEP	if	larger	diameter	pancreatic	stents	 were	 used	 (3.7	%,	 >5Fr-stent)	 compared	 to	 thinner	 ones	 (10.4	%,	 ≤5Fr-stent,	p=0.02).	Additionally,	the	PEP-risk	was	further	reduced	(to	1.4	%)	if	a	longer	stent	was	used	(>5	cm)	in	combination	with	the	 larger	diameter	(>5Fr).	However,	 these	findings	should	 be	 interpreted	with	 caution,	 since	 the	 number	 of	 patients	 actually	 receiving	 a	pancreatic	stent	was	very	low	(n=376)	compared	to	the	complete	study	base,	as	the	vast	majority	of	cases	were	excluded,	and	those	uncertainties	are	reflected	in	the	very	wide	confidence	 intervals	 received.	 However,	 it	 is	 important	 to	 generate	 hypotheses	 of	 the	type	of	prophylactic	pancreatic	stents	 that	should	be	preferred,	 since	previous	studies	have	come	to	opposite	suggestions	for	which	stents	to	use.	For	instance,	in	a	randomized	controlled	 trial,	 Chahal	 and	 co-workers	 (Chahal,	 P.,	 et	 al.,	 2009)	 preferred	 short,	 5-Fr	stents	to	long,	3-Fr	stents	because	the	former	had	fewer	adverse	effects	and	the	longer	3-Fr	stents	more	often	needed	a	repeat	ERCP	for	stent	extraction.	The	problem	with	this	study	 was	 that	 both	 the	 lengths	 and	 the	 diameters	 of	 the	 stents	 varied	 between	 the	groups,	making	it	difficult	to	interpret	the	actual	cause	of	the	differences	(i.e.,	the	length	or	the	diameter	of	the	stent).		
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On	 the	 other	 hand,	 Pakh	 and	 co-workers	 (Pahk,	 A.,	 et	 al.,	 2011)	 could	 not	 find	 any	differences	 in	 complication	 rates	 between	 4-Fr	 and	 5-Fr	 stents	 in	 a	 randomized	controlled	study,	whereas	the	opposite	was	found	by	Rashdan	(Rashdan,	A.,	et	al.,	2004),	who	claimed	that	thinner	stents	were	superior	to	thicker	ones.		All	studies	were	reviewed	in	a	meta-analysis	by	Afghani	(Afghani,	E.,	et	al.,	2014),	where	he	 concluded	 that	 prophylactic	 5-Fr	 stents	 were	 better	 than	 3-Fr	 stents,	 but	 the	protective	effect	of	the	stents	larger	than	5	Fr	still	needs	to	be	studied	prospectively,	as	there	is	certainly	a	risk	that	our	findings	of	the	lower	adverse	event	rates	in	the	group	of	stents	over	5	Fr	might	be	confounded	by	the	fact	that	the	endoscopists	were	more	prone	to	 deploy	 a	 thicker	 stent	 if	 he	 demonstrated	 a	wide	pancreatic	 duct	 during	 the	ERCP.	Also,	in	this	group	of	patients,	there	is	a	risk	that	there	might	be	an	over-representation	of	cases	of	chronic	pancreatitis,	which	has	a	protective	effect	on	PEP	(Iorgulescu,	A.,	et	
al.,	2013),	confounding	the	results	in	this	group	by	giving	a	false	low	rate	of	PEP	caused	by	the	over-representation	of	chronic	pancreatitis	rather	than	the	pancreatic	stent	itself.	On	the	other	hand,	there	are	major	strengths	associated	with	our	study.	These	strengths	include	a	large	sample	size,	which	minimizes	the	risk	for	selection	bias.	Also,	GallRiks	is	a	well-validated	registry	that	exhibits	a	97.3	%	match	with	the	patients´	medical	records	in	 previous	 studies	 (Enochsson,	 L.,	 et	 al.,	 2013).	 This	 minimizes	 the	 risk	 for	misclassification	of	the	ERCP	procedures	and	the	adverse	events.	However,	there	could	still	be	misclassification	harbored	 in	 the	study,	 since	what	we	have	 investigated	 is	 the	pancreatic	 cannulations	 actually	 recorded	 in	 the	 GallRiks	 Registry	 as	 opposed	 to	 the	ones	 actually	 taking	 place.	 Therefore,	 there	 could	 be	 inadvertent	 pancreatic	cannulations	missed	by	the	endoscopists	or	cannulations	not	recalled	by	the	endoscopist	at	the	time	of	the	registration	(recall	bias).	
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The	ERCP	procedures	 included	 in	 the	GallRiks	Registry	are	also	representative	 for	 the	wide	 clinical	 spectrum	 of	 ERCP	 investigations	 performed	 in	 Sweden,	 since	 it	 is	generated	 from	 all	 types	 of	 endoscopic	 centers	 and	 registered	 by	 endoscopists	 with	different	 experiences;	 this	 ensures	 that	 the	 ERCP	 procedures	 in	 GallRiks	 represent	 a	wide	variety	of	everyday	clinical	settings.	Currently,	about	90	%	of	all	ERCPs	performed	in	 Sweden	 are	 registered	 in	 GallRiks.	 These	 conditions	 nearly	 completely	 remove	 the	risk	of	systematic	errors.	Naturally,	 there	 are	 also	 weaknesses	 associated	 with	 the	 study.	 For	 example,	 the	assumptions	 we	 made	 that	 the	 pancreatic	 stents	 deployed	 in	 the	 study	 were	prophylactic	may	be	incorrect.	We	could	not	extract	the	exact	intention	of	the	pancreatic	stent	from	the	registry	but	only	assumed	this	from	the	indication	of	the	ERCP	procedure	(directed	 towards	 the	 bile	 duct).	 Therefore,	 any	 access	 to	 the	 pancreatic	 duct	 under	these	 circumstances	 would	 be	 accidental	 and	 thereby	 any	 stent	 deployed	 in	 the	pancreatic	duct	in	this	situation	would	have	a	prophylactic	purpose.		There	 also	 is	 a	methodological	 consideration	 that	must	 be	 taken	 into	 account,	 that	 is,	many	patients	were	excluded	from	the	original	study	base,	and	few	patients	were	left	to	study.	This	 is	reflected	 in	 the	broad	confidence	 intervals	generated	when	studying	 the	effects	of	the	pancreatic	stents.	The	risk	of	confounding	by	indication	must	also	be	mentioned	as	a	shortcoming	of	the	study	and	could	thus	be	an	explanation	of	the	findings	of	higher	intraoperative	adverse	events	rates	 in	 the	group	receiving	a	pancreatic	stent	compared	 to	 those	who	did	not.	We	do	not	have	any	explanation	other	than	that	 the	endoscopists	were	more	prone	to	deploy	a	pancreatic	stent	when	the	ERCP	procedure	was	difficult;	this	is	reflected	as	an	increase	 in	 the	 intraoperative	 adverse	 event	 rate,	 which	 is	 not	 caused	 by	 the	 stent	
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deployment	per	se	but	is	just	an	effect	of	confounding	that	is	not	compensated	for	in	the	multivariate	analysis.		Another	 potential	weakness	 of	 the	 study	 is	 the	 long	 inclusion	 time	 (2006-2014).	 This	time	 period	 includes	 changes	 in	 radiological	 and	 endoscopic	 techniques	 as	 well	 as	indications	for	an	ERCP	procedure.	The	introduction	of	the	MRI	technique	significantly	changed	 the	 indications	 for	diagnostic	ERCP	procedures,	which	have	 almost	 vanished.	Today,	 almost	 all	 ERCPs	 are	 therapeutic,	 and	 this	 has	 changed	 the	 complication	panorama.	On	the	other	hand,	 the	endoscopic	 instruments	and	devices	have	 improved	technically,	 which	 might	 have	 affected	 complication	 rates	 in	 a	 positive	 way.	 A	 final	feature	 that	 has	 been	 introduced	 in	 conjunction	 with	 ERCP	 is	 the	 use	 of	 rectally	administered	 prophylactic	 NSAIDs	 adjacent	 to	 the	 procedure,	which	 is	 also	 known	 to	reduce	PEP	rates	postoperatively.	This	use	was	only	sporadically	used	at	the	time	of	the	beginning	of	the	study	in	Sweden,	but	 it	has	gradually	increased	in	use	over	time.	This	parameter	was	not	included	in	the	GallRiks	Registry	previously	and	has	most	definitely	affected	 the	complication	rates.	Without	 it,	 it	would	be	 impossible	 for	us	 to	 study	 this	outcome	variable	previously.	However,	this	parameter	is	now	introduced	in	the	GallRiks	Registry,	and	it	is	available	to	investigate	or	compensate	for	in	future	studies.	So	ideally,	it	would	have	been	better	to	perform	the	study	over	a	shorter	time	span	to	include	this	parameter	 throughout	 the	entire	 time	period;	however,	 this	would,	on	the	other	hand,	have	minimized	the	number	patients	included	in	the	study.		A	further	limitation	of	the	study	is	that	neither	the	brand	nor	the	type	of	pancreatic	stent	(apart	 from	 length	 and	diameter)	were	 registered	 in	 the	GallRiks	Registry,	 and	 hence	factors	like	pigtail	flanges	on	the	stent	could	not	be	studied.		In	conclusion,	our	study	has	demonstrated	that	the	PEP	risk	was	increased	in	the	ERCP	procedure	 where	 the	 pancreatic	 duct	 was	 cannulated,	 which	 is	 in	 line	 with	 previous	
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